Loading
Ursula Matulonis led the MIRASOL trial that gave ovarian cancer its first ADC with a survival benefit.
Ursula A. Matulonis is Chief of the Division of Gynecologic Oncology at Dana-Farber Brigham Cancer Center. She is a gynaecologic oncologist known for leading the MIRASOL trial of mirvetuximab soravtansine, which gave ovarian cancer its first antibody-drug conjugate, as well as trials of PARP inhibitors and bevacizumab combinations. Her selected paper reports mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancer. She continues to lead trials of PARP inhibitors such as olaparib and of ADCs in ovarian cancer.
| Title | Journal | Year |
|---|---|---|
| Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer | New England Journal of Medicine | 2023 |
Shares MIRASOL / GOG-3045, Folate receptor alpha, Mirvetuximab soravtansine, PARP.
Shares Folate receptor alpha, Mirvetuximab soravtansine, PARP, Olaparib.
Shares PARP, Olaparib, Ovarian cancer.
Shares PARP, Olaparib, Ovarian cancer.
Shares PARP, Dana-Farber Brigham Cancer Center, Ovarian cancer.